| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers N > Headlines for Nymox Pharmaceutical Corp. > News item |
Nymox safety data finds no serious side effects for prostatic hyperplasia drug
By Elaine Rigoli
Tampa, Fla., Feb. 23 - Nymox Pharmaceutical Corp. announced that its latest internal review of the current available safety data for its ongoing, multi-center, phase 2 trial of NX-1207 has revealed no serious drug side effects.
NX-1207 is Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH).
BPH afflicts about half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream and other problems.
NX-1207 has completed two earlier phase 1 and 2 trials where the drug produced on average more than 23% prostate shrinkage in one month with minimal side effects, according to a company news release.
Overall there have been no sexual side effects, and a better side effect profile compared to existing drugs. The symptomatic improvement in earlier trials reached 10 points on the BPH symptom score, which is far superior to available drugs, and compares to invasive and surgical treatments, the company said.
On Jan. 23, Nymox reported that the Independent Data Monitoring Committee for the trial of NX-1207 had given a positive recommendation based on evaluation of the efficacy and safety data at that point in time. The Independent Data Monitoring Committee is an arm's length independent body that has examined unblinded trial results and reached a favorable conclusion and has recommended continuation of the trial.
Nymox is a biopharmaceutical company specializing in the research and development of therapeutics and diagnostics for the aging population. The company is based in Hasbrouck Heights, N.J.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.